|
|
||||||||
1Department of Internal Medicine, Pulmonary and Critical Care Division, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, Ohio; 2Department of Internal Medicine, Division of Pulmonary and Critical Medicine, University of Michigan Medical School, Ann Arbor, Michigan; and 3Department of Internal Medicine, Pulmonary and Critical Care Division, Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa
Submitted 7 December 2004 ; accepted in final form 19 February 2005
Neuregulin-1 (NRG-1), binding to the human epidermal growth factor receptor HER2/HER3, plays a role in pulmonary epithelial cell proliferation and recovery from injury in vitro. We hypothesized that activation of HER2/HER3 by NRG-1 would also play a role in recovery from in vivo lung injury. We tested this hypothesis using bleomycin lung injury of transgenic mice incapable of signaling through HER2/HER3 due to lung-specific dominant-negative HER3 (DNHER3) expression. In animals expressing DNHER3, protein leak, cell infiltration, and NRG-1 levels in bronchoalveolar lavage fluid increased after injury, similar to that in nontransgenic littermate control animals. However, HER2/HER3 was not activated, and DNHER3 animals displayed fewer lung morphological changes at 10 and 21 days after injury (P = 0.01). In addition, they contained 51% less collagen in injured lungs (P = 0.04). Transforming growth factor-
1 did not increase in bronchoalveolar lavage fluid from DNHER3 mice compared with nontransgenic littermate mice (P = 0.001), suggesting that a mechanism for the decreased fibrosis was lack of transforming growth factor-
1 induction in DNHER3 mice. Severe lung injury (0.08 units bleomycin) resulted in 80% mortality of nontransgenic mice, but only 35% mortality of DNHER3 transgenic mice (P = 0.04). Thus inhibition of HER2/HER3 signaling protects against pulmonary fibrosis and improves survival.
lung injury; bleomycin; growth factors; receptor tyrosine kinases; neuregulin
This article has been cited by other articles:
![]() |
W. D. Hardie, C. Davidson, M. Ikegami, G. D. Leikauf, T. D. Le Cras, A. Prestridge, J. A. Whitsett, and T. R. Korfhagen EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-{alpha}-induced pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, June 1, 2008; 294(6): L1217 - L1225. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Purevdorj, K. Zscheppang, H. G. Hoymann, A. Braun, D. von Mayersbach, M.-J. Brinkhaus, A. Schmiedl, and C. E. L. Dammann ErbB4 deletion leads to changes in lung function and structure similar to bronchopulmonary dysplasia Am J Physiol Lung Cell Mol Physiol, March 1, 2008; 294(3): L516 - L522. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Faress, D. E. Nethery, E. F. O. Kern, R. Eisenberg, F. J. Jacono, C. L. Allen, and J. A. Kern Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2 J Appl Physiol, December 1, 2007; 103(6): 2077 - 2083. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Nethery, S. Ghosh, S. C. Erzurum, and J. A. Kern Inactivation of neuregulin-1 by nitration Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L287 - L293. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |